FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015364291> ?p ?o ?g. }

• W3015364291 endingPage "2389" @default.
• W3015364291 startingPage "2370" @default.
• W3015364291 abstract "Processing procedures for inducing domain size reduction and/or amorphous phase generation can be crucial for enhancing the bioavailability of active pharmaceutical ingredients (APIs). It is important to quantify these reduced coherence phases and to detect and characterize associated structural changes, to ensure that no deleterious effects on safety, function, or stability occur. Here, X-ray powder diffraction (XRPD), total scattering pair distribution function (TSPDF) analysis, and solid-state nuclear magnetic resonance spectroscopy (SSNMR) have been performed on samples of GSK2838232B, an investigational drug for the treatment of human immunodeficiency virus (HIV). Preparations were obtained through different mechanical treatments resulting in varying extents of domain size reduction and amorphous phase generation. Completely amorphous formulations could be prepared by milling and microfluidic injection processes. Microfluidic injection was shown to result in a different local structure due to dispersion with dichloromethane (DCM). Implications of combined TSPDF and SSNMR studies to characterize molecular compounds are also discussed, in particular, the possibility to obtain a thorough structural understanding of disordered samples from different processes." @default.
• W3015364291 created "2020-04-17" @default.
• W3015364291 creator A5009162024 @default.
• W3015364291 creator A5021952359 @default.
• W3015364291 creator A5044252087 @default.
• W3015364291 creator A5053495413 @default.
• W3015364291 creator A5065794019 @default.
• W3015364291 creator A5070831837 @default.
• W3015364291 creator A5079106536 @default.
• W3015364291 creator A5079725757 @default.
• W3015364291 date "2020-04-15" @default.
• W3015364291 modified "2023-10-16" @default.
• W3015364291 title "Local Structural Effects Due to Micronization and Amorphization on an HIV Treatment Active Pharmaceutical Ingredient" @default.
• W3015364291 cites W1813688020 @default.
• W3015364291 cites W1969105492 @default.
• W3015364291 cites W1979628906 @default.
• W3015364291 cites W1983319174 @default.
• W3015364291 cites W1983874564 @default.
• W3015364291 cites W1984009385 @default.
• W3015364291 cites W1987357242 @default.
• W3015364291 cites W1994691989 @default.
• W3015364291 cites W2000091303 @default.
• W3015364291 cites W2003098145 @default.
• W3015364291 cites W2014577502 @default.
• W3015364291 cites W2027484002 @default.
• W3015364291 cites W2035065700 @default.
• W3015364291 cites W2036138787 @default.
• W3015364291 cites W2038453179 @default.
• W3015364291 cites W2041315714 @default.
• W3015364291 cites W2047226339 @default.
• W3015364291 cites W2050130513 @default.
• W3015364291 cites W2050283230 @default.
• W3015364291 cites W2055516309 @default.
• W3015364291 cites W2063606088 @default.
• W3015364291 cites W2064468313 @default.
• W3015364291 cites W2066271048 @default.
• W3015364291 cites W2072253461 @default.
• W3015364291 cites W2073456732 @default.
• W3015364291 cites W2079505753 @default.
• W3015364291 cites W2082076695 @default.
• W3015364291 cites W2086710911 @default.
• W3015364291 cites W2086945873 @default.
• W3015364291 cites W2088194495 @default.
• W3015364291 cites W2091308571 @default.
• W3015364291 cites W2107326912 @default.
• W3015364291 cites W2112908277 @default.
• W3015364291 cites W2114200644 @default.
• W3015364291 cites W2122798985 @default.
• W3015364291 cites W2133974199 @default.
• W3015364291 cites W2145425943 @default.
• W3015364291 cites W2151823004 @default.
• W3015364291 cites W2155128650 @default.
• W3015364291 cites W2213046073 @default.
• W3015364291 cites W2283461478 @default.
• W3015364291 cites W2335434301 @default.
• W3015364291 cites W2460756521 @default.
• W3015364291 cites W2525866120 @default.
• W3015364291 cites W2784103179 @default.
• W3015364291 cites W2790220533 @default.
• W3015364291 cites W2806439465 @default.
• W3015364291 cites W2888833305 @default.
• W3015364291 cites W2939981142 @default.
• W3015364291 cites W2945221836 @default.
• W3015364291 cites W2960536748 @default.
• W3015364291 cites W2974687452 @default.
• W3015364291 cites W876552277 @default.
• W3015364291 cites W937898667 @default.
• W3015364291 doi "https://doi.org/10.1021/acs.molpharmaceut.0c00122" @default.
• W3015364291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32293895" @default.
• W3015364291 hasPublicationYear "2020" @default.
• W3015364291 type Work @default.
• W3015364291 sameAs 3015364291 @default.
• W3015364291 citedByCount "14" @default.
• W3015364291 countsByYear W30153642912020 @default.
• W3015364291 countsByYear W30153642912021 @default.
• W3015364291 countsByYear W30153642912022 @default.
• W3015364291 countsByYear W30153642912023 @default.
• W3015364291 crossrefType "journal-article" @default.
• W3015364291 hasAuthorship W3015364291A5009162024 @default.
• W3015364291 hasAuthorship W3015364291A5021952359 @default.
• W3015364291 hasAuthorship W3015364291A5044252087 @default.
• W3015364291 hasAuthorship W3015364291A5053495413 @default.
• W3015364291 hasAuthorship W3015364291A5065794019 @default.
• W3015364291 hasAuthorship W3015364291A5070831837 @default.
• W3015364291 hasAuthorship W3015364291A5079106536 @default.
• W3015364291 hasAuthorship W3015364291A5079725757 @default.
• W3015364291 hasConcept C127413603 @default.
• W3015364291 hasConcept C171250308 @default.
• W3015364291 hasConcept C181389837 @default.
• W3015364291 hasConcept C185592680 @default.
• W3015364291 hasConcept C192562407 @default.
• W3015364291 hasConcept C42360764 @default.
• W3015364291 hasConcept C43617362 @default.
• W3015364291 hasConcept C45904493 @default.
• W3015364291 hasConcept C56052488 @default.
• W3015364291 hasConcept C71924100 @default.
• W3015364291 hasConcept C8010536 @default.
• W3015364291 hasConcept C98274493 @default.

• next